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Abstract
Background: Aberrations of allelic replication timing are epigenetic markers observed in peripheral blood cells of 
cancer patients. The aberrant markers are non-cancer-type-specific and are accompanied by increased levels of 
sporadic aneuploidy. The study aimed at following the epigenetic markers and aneuploidy levels in cells of patients 
with haematological malignancies from diagnosis to full remission, as achieved by allogeneic stem cell transplantation 
(alloSCT).
Methods: TP53 (a tumor suppressor gene assigned to chromosome 17), AML1 (a gene assigned to chromosome 21 
and involved in the leukaemia-abundant 8;21 translocation) and the pericentomeric satellite sequence of 
chromosome 17 (CEN17) were used for replication timing assessments. Aneuploidy was monitored by enumerating 
the copy numbers of chromosomes 17 and 21. Replication timing and aneuploidy were detected cytogenetically using 
fluorescence in situ hybridization (FISH) technology applied to phytohemagglutinin (PHA)-stimulated lymphocytes.
Results: We show that aberrant epigenetic markers are detected in patients with hematological malignancies from the 
time of diagnosis through to when they are scheduled to undergo alloSCT. These aberrations are unaffected by the 
clinical status of the disease and are displayed both during accelerated stages as well as in remission. Yet, these markers 
are eradicated completely following stem cell transplantation. In contrast, the increased levels of aneuploidy 
(irreversible genetic alterations) displayed in blood lymphocytes at various stages of disease are not eliminated 
following transplantation. However, they do not elevate and remain unchanged (stable state). A demethylating anti-
cancer drug, 5-azacytidine, applied in vitro to lymphocytes of patients prior to transplantation mimics the effect of 
transplantation: the epigenetic aberrations disappear while aneuploidy stays unchanged.
Conclusions: The reversible nature of the replication aberrations may serve as potential epigenetic blood markers for 
evaluating the success of transplant or other treatments and for long-term follow up of the patients who have 
overcome a hematological malignancy.
Background
Genes of the parental genomes in diploid organisms usu-
ally maintain functional symmetry, namely, the two
alleles operate or shut off concomitantly in what is called
biallelic expression. However, a subset of genes exhibits
allele-specific expression (monoallelic expression) in
which only one allele operates and its counterpart
remains silent [1,2]. The determination of whether or not
allelic counterparts of a gene retain functional symmetry
is usually fixed at early stages of development and is an
essential aspect of a usually heritable epigenomic contour
passed down to the cell's progeny (reviewed in [2]).
Whatever the mechanisms involved in the maintenance
and selection of an allele for an allele-specific epigenetic
profile, it is usually accompanied by the two alleles main-
taining different chromatin structures and/or differential
methylation capacities in which asynchronous DNA rep-
lication plays a decisive role (reviewed in [3]). Specifically,
an asynchronous pattern of allelic replication (in contrast
to a highly synchronous pattern characterizing alleles of
biallelically expressed genes) was shown for all known
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types of monoallelically expressed genes and not neces-
sarily in the tissue of expression. These include (i)
imprinted genes [4-8]; (ii) genes subjected to X-chromo-
some inactivation [9,10]; and (iii) genes undergoing allelic
exclusion [11-13].
The fluorescence in situ hybridization (FISH) replica-
tion assay is the method of choice for evaluating the tem-
poral order of allelic replication [11-14]. Applying the
FISH replication assay to biallelically expressed genes in
cells of cancer patients indicated that malignancy is asso-
ciated with non-disease-specific loss of the normally syn-
chronous pattern of replication of certain loci. Briefly,
biallelically expressed genes, -- such as TP53, AML1, RB1,
C-MYC  and HER2  (which normally display a synchro-
nous mode of replication) -- exhibit an asynchronous pat-
tern of replication (similar to that of monoallelically
expressed genes) in bone marrow cells [15] and blood
lymphocytes [16] of patients with hematological malig-
nancies, and even in blood lymphocytes of patients with
solid tumors, such as renal cell carcinoma [7] or prostate
cancer [8,17].
Furthermore, chromosome-specific sequences (peri-
centromeric, unexpressed DNA arrays), which normally
display synchrony in replication of homologous counter-
parts, similar to biallelically expressed genes, change their
inherent replication mode and replicate asynchronously
in lymphocytes of patients with cancer, including ovarian
[18], hematological [16] and prostate [8,17] malignancies.
This change in the replication patterns of the pericentro-
meric arrays is accompanied by chromosomal malsegre-
gation, which results in increased aneuploidy in the
patients' cells [8,16,18].
The cancer-mediated loss of synchronous replication
appears to be a reversible epigenetic phenomenon associ-
ated with abnormal methylation capacity since it was
reversed to the normal following in vitro application of
the methylation inhibiting drug 5-azacytidine (AZA).
This demethylating agent is known to induce the re-
expression of epigenetically silenced genes [19] and has
recently been approved for the therapy of myeloid malig-
nancies [20]. The readjusted synchronous replication in
the presence of AZA was demonstrated in blood lympho-
cytes of cancer patients [8,16,17]. In contrast, the
increased aneuploidy in the lymphocytes of the patients
remains unchanged following AZA application [8,16].
Interestingly, the short term effect of granulocyte col-
ony-stimulating factor (G-CSF), a key haematopoietic
growth factor, used clinically, in healthy individuals (sib-
lings as well as unrelated stem cell donors) to obtain cells
for allogeneic transplantations, resembles, in this respect,
the effects of malignant disease on blood cells. Briefly, G-
CSF applied to normal healthy individuals, in vivo or in
vitro, leads to a loss of synchronous replication of bialleli-
cally expressed genes in their blood lymphocytes, which
is eliminated in vitro with AZA [21]. G-CSF concomi-
tantly causes increased aneuploidy, which remains
unchanged following in vitro application of the demethy-
lating drug. Yet, the long-term effect of G-CSF following
in vivo application to healthy stem cell donors resembles
the effect of AZA applied in vitro to cells of cancer
patients -- the aberrant replication is set to normal
whereas the increased aneuploidy remains unchanged
[21].
The present study was carried out to follow gene repli-
cation patterns (epigenetic properties) and aneuploidy
levels (genetic properties) in patients' lymphocytes prior
to and following successful allogeneic stem cell transplan-
tation (alloSCT). Specifically, we show here that (i) the
loss of synchronous replication of loci that normally rep-
licate synchronously, in the patients' cells prior to
alloSCT is set to normal following transplantation, while
the increased aneuploidy remains abnormal; and (ii) AZA
applied in vitro to lymphocytes of patients prior to
alloSCT mimics the effect of alloSCT -- the aberrant epi-
genetic profiles observed in lymphocytes of patients prior
to alloSCT are set to normal, whereas the accompanying
genetic aberrations are unaffected.
Methods
Peripheral Blood Samples
Sixty-four peripheral blood samples (5 ml, each) obtained
from four groups of consenting individuals were investi-
gated: (i) 20 from normal, cancer-free individuals, used as
controls (hereafter termed CON); (ii) 20 from patients
with hematological malignancies taken at diagnosis
(hereafter termed ADI); (iii) 14 of patients with hemato-
logical malignancies obtained prior to allogeneic stem
cell transplantation (alloSCT) (hereafter termed PRE);
and (iv) 10 from patients with hematological malignan-
cies taken following alloSCT, each displaying 100% donor
chimerism, as judged from analyses of bone-marrow
aspirates (hereafter termed POST). None of the investi-
gated individuals was included in more than one group.
T he subjects of each group were chosen at random in
order to avoid any bias in patients' selection.
The patients suffered from various hematological
malignancies. Of the 20 ADI individuals 9 had acute
myelogenous leukemia (AML), 8 chronic myelogenous
leukemia (CML), 2 acute lymphoblastic leukemia (ALL),
and 1 multiple myeloma (MM). Of the 14 PRE individu-
als, 4 had AML (3 in remission and one not), 8 CML (6 in
the chronic and 2 in the accelerated phase), 1 ALL (in
remission) and 1 non-Hodgkins lymphoma (NHL, not in
remission). Of the POST subjects, 4 had AML, 4 had
CML, 1 ALL and 1 NHL (all at full remission).
The ADI group included 9 females and 11 males, rang-
ing in age from 3 to 80 years (median and mean values of
35.0 and 37.2 years, respectively). The PRE group con-Nagler et al. BMC Cancer 2010, 10:230
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tained 5 females and 9 males, ranging from 11 to 56 years
(median and mean of 37.5 and 37.0 years, respectively).
The POST group included 3 females and 7 males, ranging
from 13-51 years (median and mean of 32.0 and 32.3
years, respectively). The CON group consisted of 8
females and 12 males, ranging from 11-65 years (median
and mean of 36.0 and 35.0 years, respectively).
In addition, we examined 14 peripheral blood samples
( 5  m l  e a c h )  o b t a i n e d  f r o m  1 4  c o n s e n t i n g  u r o l o g i c a l
patients, referred to prostate biopsy because of suspected
prostate cancer. This group of male patients ranged in age
53-78 years, with median and mean values of 66.5 and
65.1 years, respectively. Following biopsy, four out of the
14 patients were diagnosed with prostate cancer and the
rest (10 individuals) were found to be cancer-free. Of the
10 cancer-free individuals three were found to suffer from
chronic prostate inflammation and seven from benign
prostate hyperplasia.
Bone Marrow Samples
Twenty-six bone marrow samples, obtained from con-
s e n t i n g  s u b j e c t s  ( 2  m l  e a c h ) ,  w e r e  a l s o  t e s t e d .  T h e y
included: (i) 12 exemplars from a new group of cancer-
free individuals, 4 females and 8 males, ranging in age
from 7-54 years; and (ii) 14 from patients in the PRE
group, one sample from each of them.
Cell Cultures
Cell cultures were set up according to the standard proto-
col for karyotype analysis [18]. Briefly, aliquots of periph-
eral blood or bone marrow aspirates were introduced into
F-10 medium supplemented with 20% fetal calf serum,
0.2% heparin and 1% penicillin/streptomycin antibiotic
solution (Biological Industries, Israel). For blood cell cul-
turing, this medium was additionally supplemented by
3% phytohemagglutinin (PHA) to stimulate cell division.
Each of the blood samples derived from the CON, ADI
and PRE patients were incubated in duplicate, one in the
enhanced F-10 medium containing PHA and the second
in a medium containing 10-7  M 5-azacytidine (AZA;
Sigma, USA) as well as PHA.
After 72 hours at 37°C, colchicine (Sigma, USA) was
added (to a final concentration of 5 × 10-7 M) for one hr,
followed by a hypotonic treatment (0.075 M KCl at 37°C,
for 15 min) and four washes, each with a fresh, cold (-
20°C) 3:1 methanol:acetic acid solution. The cell suspen-
sions were stored at -20°C until used for FISH.
Slide Preparation
The stored cell suspensions prepared for hybridization
were washed twice in a 3:1 methanol: acetic acid solution,
diluted until the suspension became slightly cloudy and
then approximately 5 μl of the suspension was dropped
onto the marked circles of two-well slide glasses. The
two-well slides were obtained from Insitus Biotechnolo-
gies (Albuquerque, NM, USA) and used without any pre-
treatment.
Probes
W e  t e s t e d  f o u r  l o c i  u s i n g  d i r e c t l y  l a b e l e d  c o m m e r c i a l
probes obtained from Vysis: (i) the TP53 probe (32-
190006); (ii) the AML1 probe (LSI 21; 32-190002); (iii) the
α-satellite probe specific for centromere 17 (32-130017,
hereafter marked as CEN17); and (iv) the SNRPN probe
(32-190004). The TP53 probe identifies an archetypical
tumor suppressor gene mapped to 17p13.1. The AML1
probe maps to chromosome 21q22, it is also used for the
enumeration of chromosome 21. The centromere-spe-
cific probe CEN17, usually used for the enumeration of
chromosome 17, identifies a specific non-coding repeti-
tive pericentromeric array on this chromosome. The
SNRPN probe identifies the Prader-Willi/Angelman syn-
drome-imprinted region on 15q11-13.
In-Situ Hybridization
Probes were diluted in Ingen's DenHyb solutions (Insitus
Biotechnologies), in catalog #D001 (1:200) for CEN17
and in catalog #D003 (1:100) for AML1 and (1:50) for
TP53 and SNRPN. We used these to replace the hybrid-
ization solutions supplied with the probes. Five μl of the
probe solution were placed on the target area of the sam-
ple slides and covered with a 12 mm round silanized cov-
erslip (Insitus Biotechnologies) and sealed with rubber
cement. The slides were placed on a preheated aluminum
slide tray (Insitus Biotechnologies) at 76°C and denatured
for 6 min at that temperature. The slide-filled aluminum
slide tray was then transferred into a HybBox (Insitus
Biotechnologies) covered and allowed to hybridize over-
night.
Detection
Post hybridization wash for probe TP53 was carried out
by immersing the slides in 4 × saline sodium citrate (1×
SSC = 150 mM NaCl, 15 mM sodium citrate) for five min
at room temperature. Post hybridization washes for
probe AML1 consisted of immersing the slides for 20 sec
in 0.4 × SSC, pH 7.0 with 0.3% NP40 Nonidet P4 deter-
gent), followed by 20 sec in 2.0 × SSC with 0.1% NP40 at
60°C in a shaking water bath. The post hybridization
washing of the CEN17 was carried out in the same solu-
tions as the AML1 probe, with the first wash carried out
at 75°C for 2 min and the second at the same temperature
for 1 min. After draining off excess liquid and brief dry-
ing, the slides were treated with 15 μl/slide of a solution
of antifade containing 3 μg/ml of 4,6-diamidino-2-phe-
nylindole (DAPI) as the counterstain (Vector Laborato-
ries, Inc., Burlingame, CA, USA). Slides were covered
with glass-coverslips (22 × 60 mm) and stored at -20°C till
analyzed (which could take place anywhere between 1 hr
and two days).Nagler et al. BMC Cancer 2010, 10:230
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Cytogenetic Evaluation
Slides were analyzed blindly on an Olympus BH2 fluores-
cent microscope, using a triple band-pass filter (Chroma
Technology, Brattleboro, VT, USA). The FISH replication
assay was used here to follow the degree of synchrony in
allelic replication (see Introduction). Accordingly, follow-
ing hybridization, the fluorescence signals are divided
into two categories, a single dot-like signal (designated:
"singlet" or "S"), representing a yet non-replicated DNA
sequence and a duplicated bipartite signal (designated:
"doublet" or "D"), indicating a replicated sequence. Thus,
two allelic counterparts replicating synchronously display
a high frequency of cells with the two counterparts at the
same replication status, either both non-replicated (SS
cells; Figure 1A) or both replicated (DD cells; Figure 1B),
and a low frequency of cells having one replicated and
one non-replicated allele (SD cells; Figure 1C). In con-
trast, allelic counterparts replicating asynchronously
exhibit a high frequency of SD cells. Hence, the SD cell
frequency reveals the degree of asynchrony in allelic rep-
lication.
For the replication analyses, at least 100 interphase cells
from each sample exhibiting two distinct well-defined
fluorescence signals were scored for each treatment and
probe under study. In each cell population, we noted the
frequency (as a percentage, %) of SD cells out of the total
population of interphase cells exhibiting two well defined
fluorescence signals. We differentiated between a doublet
signal and two singlets by ensuring that the two spots
were not separated from each other by a distance greater
than the diameter of the largest spot.
For detecting the level of aneuploidy, at least 200 inter-
phase cells from each sample of blood preparations used
for the replication analyses and treatments were screened
for the numbers of chromosomes 17 and 21. For these
determinations, we utilized, respectively, one-color FISH
with the CEN17 and the AML1 probes. In each cell, the
number of hybridization signals was recorded, and the
frequency of cells with one signal was used to estimate
the level of monosomic cells, the frequency of cells with
three or more signals revealed the level of multisomy.
Thus, the sum of the multisomy and the monosomy fre-
quencies reflects the level of aneuploidy for the chromo-
some in question. The FISH interphase assay, as applied
here, is currently the method of choice for detecting
chromosome aneuploidy [reviewed in [21]].
Statistical Analysis
The statistical significance of the difference between two
cell populations was determined using the two-tailed Stu-
dent's t-test (Microsoft Excel).
Ethical Basis
This study was approved by the Institutional Helsinki
Committee and the Israel Ministry of Health.
Results
The cancer-related aberrant asynchronous replication is 
abolished following stem cell transplantation
We have examined the frequency of SD cells of two genes
(TP53, AML1) and a non-coding repetitive pericentro-
meric array (CEN17) in blood cell samples of patients
with hematological malignancies, obtained pre and post
alloSCT (PRE and POST). Corresponding SD values of
the PRE and POST groups of samples were compared to
one another and each to the values obtained in blood
samples of cancer-free subjects (CON) and in patients
with hematological malignancies taken at diagnosis
(ADI). The SD values for TP53, AML1, and CEN17 in the
POST group were low, similar to those of the CON
group. Yet, each of the three tested loci in the PRE group
showed high SD values, similar to those observed in the
ADI group (solid bars in Figure 2; Columns 1-3 in Table
1). The differences in the SD values between the POST
and PRE groups were highly significant, P < 10-6 for TP53
and AML1, and P < 10-7 for CEN17 (Table 1). The mean
SD values for TP53, CEN17 and  AML1  in the POST
group were similar to those in the CON group, but were
almost half of those found in the PRE and ADI groups.
Each SD value in the POST samples exhibited highly sig-
nificant differences from the corresponding values in the
PRE and ADI groups (Table 1).
The SD values for TP53, AML1 and CEN17 are nor-
mally significantly lower (as exemplified by the CON
group) than those of an imprinted locus (exemplified here
by the SNRPN gene) (Figure 2A; Table 2, first row). How-
ever, blood samples of the PRE group (as well as the ADI
group) had high SD values, similar to those characteriz-
ing an imprinted locus (Table 2; solid bars in Figure 2).
Yet, following transplantation, i.e., in the cell samples of
the POST subgroup, the SD values of the tested loci were
Figure 1 Fluorescent signals in PHA-stimulated lymphocytes at 
interphase following FISH with the CEN17 probe. (A) Cell with two 
singlets (SS cell), in which neither allele has replicated; (B) cell with two 
doublets (DD cell), in which both alleles have replicated; and (C) cell 
with one singlet and one doublet (SD cell), a S-phase cell in which one 
allele has replicated while its partner has still to do so.Nagler et al. BMC Cancer 2010, 10:230
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Figure 2 Mean SD values in blood samples grown with and without AZA. (A) Control samples (20 cases); (B) samples from patients with hema-
tological malignancies obtained at diagnosis (20 cases); (C) samples from patients with malignancies taken prior to alloSCT transplantation (14 cases); 
and (D) samples from patients with hematological malignancies taken following alloSCT (10 cases). AZA - 5-azacytidine.
Table 1: Levels of significance (P) of the differences with respect to SD values and aneuploidy levels.
TP53 CEN17 AML1 Chromosome 17 Chromosome 21
CON
Vs.
ADI
P < 10-15 P < 10-14 P < 10-18 P < 10-6 P < 10-13
CON
Vs.
PRE
P < 10-9 P < 10-12 P < 10-6 P < 10-7 P < 10-4
CON
Vs.
POST
P > 0.25 P > 0.25 P > 0.85 P < 10-10 P < 10-5
POST
Vs.
ADI
P < 10-7 P < 10-8 P < 10-8 P > 0.55 P > 0.05
POST
Vs.
PRE
P < 10-6 P < 10-7 P < 10-6 P > 0.10 P > 0.20
ADI
Vs.
PRE
P > 0.10 P > 0.35 P > 0.5 P > 0.05 P < 0.002
CON - samples of cancer free subjects (20 cases); ADI - samples of patients with hematological malignancies obtained at diagnosis (20 cases); 
PRE - samples of patients with hematological malignancies taken prior to alloSCT (14 cases); POST - samples of patients with hematological 
malignancies taken following alloSCT (10 cases); SD values - columns 1-3; and aneuploidy levels - columns 4 and 5.Nagler et al. BMC Cancer 2010, 10:230
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set to normal and as such deviated significantly (P < 10-7;
Table 2, last row) from those of the imprinted SNRPN.
Thus the three independent genetic loci under study in
patients with hematological malignancies show abnormal
replication properties (loss of synchrony), but following
alloSCT, all three regain their normal inherent replication
mode (solid bars in Figure 2; Tables 1 and 2).
Following stem cell transplantation malignancy-associated 
aneuploidy is unchanged
Applying FISH using the CEN17  and  AML1  probes
(enabling the enumeration of chromosomes 17 and 21);
we examined the numbers of these chromosomes at
interphase in blood cell samples of the four groups of
subjects under study. The mean and standard deviations
of the frequency of cells showing aneuploidy, changes in
the normal copy number for the POST group was 16.8 ±
2.2% (ranging from 13.5-20.5%) for chromosome 17, and
12.0 ± 2.8% (ranging from 8.0-16.5%) for chromosome 21.
These values appear to be significantly higher (P < 10-10
and P < 10-5 for chromosomes 17 and 21, respectively)
than the corresponding values obtained in the CON
group, ranging from 4.0-10.5% for chromosome 17, and
0.5-9.0% for chromosome 21, with mean values of 7.0 ±
1.7% and 5.0 ± 2.6%, respectively (solid bars in Figure 3).
In contrast, no differences were found in the frequency of
cells with aneuploidy, for the two chromosomes under
test, between cells of the POST group and those of each
of the other two groups of patients with hematological
malignancies (solid bars in Figure 3; Columns 4 and 5 in
Table 1).
The high level of aneuploidy in the POST group of
blood samples was manifested both with regard to mono-
somy (a loss of one chromosomal copy) as well as multi-
somy (a gain of one or more chromosomal copies) for
each of the two chromosomes tested. For each chromo-
some, the monosomy as well as the multisomy values, in
the cells of the POST group were similar to the corre-
sponding values in the PRE and ADI groups and signifi-
cantly higher than those observed in the CON group
(data not shown).
Finally, when all of the 64 blood cell samples studied are
compared with respect to two factors -- (i) the mean SD
values for TP53, CEN17 and AML1; and (ii) the mean
aneuploidy value of chromosomes 17 and 21 -- it is
clearly seen that the cancer-related aberrant SD value (an
epigenetic marker) is set back to the normal following
transplantation, while the cancer-associated increase in
aneuploidy level (a genetic marker) is not readjusted to
the background level (Figure 4).
Clearly , the loss of synchrony as well as the elevated
aneuploidy in the patients' cells was neither type-of-
malignancy specific nor phase-of-malignancy specific.
This is evident from the wide consistency in the values
within the PRE group, representing various hematologi-
cal malignancies at different stages of severity, including
remission (1 ALL and 3 AML cases), chronic (6 CML
cases) and accelerated (1 NHL, 1 AML and 2 CML cases)
(Figure 4). Similarly, within the ADI group (2 ALL, 9
AML, 8 CML and 1 MM cases) a consistency in the repli-
cation and aneuploidy values was observed in the various
conditions (Figure 4).
Table 2: Levels of significance (P) of the differences between the SD values for the designated loci in respect to those of 
SNRPN.
TP53 CEN17 AML1
CON
(n = 20)
P < 10-10 P < 10-10 P < 10-10
ADI
(n = 20)
P > 0.55 P > 0.65 P < 0.03
PRE
(n = 14)
P > 0.40 P > 0.75 P > 0.95
POST
(n = 10)
P < 10-7 P < 10-7 P < 10-7
CON - samples of cancer free subjects; ADI - samples of patients with hematological malignancies obtained at diagnosis; PRE - samples of 
patients with hematological malignancies taken prior to alloSCT; POST - samples of patients with hematological malignancies taken 
following alloSCT; and n - Number of cases tested within each group for each locus. Each value (for each designated locus in each group of 
samples) is in respect to the levels of SD for SNRPN in the blood samples of the CON group (20 cases). The SD level for SNRPN in the ADI group 
was similar (P > 0.70) to that obtained in the CON group (see last bars in Figure 1A and 1B).Nagler et al. BMC Cancer 2010, 10:230
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The cancer-related asynchronous replication is revealed in 
bone marrow cells
Bone marrow cells of the PRE group of patients showed
high SD frequencies for TP53 and AML1, similar to those
in the patients' blood samples, yet significantly higher (P
< 10-7 and P < 10-8, for TP53 and AML1, respectively)
than those from bone marrow cells of cancer-free indi-
viduals. Specifically, the frequency of SD cells in bone
marrow samples of the pre transplantation patients
ranged from 25.0-46.0% and 29.0-49.0% for TP53  and
AML1, respectively, whereas the corresponding values
for cancer free individuals ranged respectively from 10.7-
23.2% and 12.0-25.5% (Figure 5).
Thus, the bone marrow results indicate that the cancer-
related replication aberration, shown previously in blood
cells (Figure 2C), is revealed also in the bone marrow cells
and it further shows that the loss of synchrony is non-
specific to the type or stage of the hematological disease.
The bone marrow samples derived from pre transplanta-
tion patients differing in the type and stage of malignancy
all displayed similar (high) SD values for each gene stud-
ied, which differed from the normal values characterizing
bone marrow cells of healthy individuals (Figure 5).
Asynchronous replication is not observed in lymphocytes 
of cancer-free individuals with chronic prostate 
inflammation
In a related study, we have examined the frequency of SD
cells of two loci (AML1 and CEN17) in blood cell samples
Figure 3 Mean frequency of aneuploidic cells in blood samples grown with and without AZA. (A) Control samples (20 cases); (B) samples of 
patients with hematological malignancies obtained at diagnosis (20 cases); (C) samples of patients with malignancies taken prior to alloSCT transplan-
tation (14 cases); and (D) samples of patients with haematological malignancies taken following alloSCT (10 cases). Chro - Chromosome; and AZA - 5-
azacytidine.
Figure 4 Distribution of blood samples according to their SD cell 
frequency and aneuploidy level. The SD value of each sample is ex-
pressed by the mean of the SD cell frequency values of TP53, CEN17, 
and AML1; and the aneuploidy is the mean of the aneuploidy values of 
chromosomes 17 & 21.Nagler et al. BMC Cancer 2010, 10:230
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of three subgroups of urological male patients: (i) patients
with prostate cancer (four cases); (ii) cancer-free patients
suffering from prostate chronic inflammation (three
cases); and (iii) matching cancer-free patients with
benign prostate hyperplasia, who were not found to suf-
fer from infectious disease (seven cases). This study was
performed, in part, to see whether the high SDs of
patients with malignancies were not simply a result of
inflammation. The SD values of samples derived from the
cancer-free patients with chronic inflammation were
similar to those of the cancer-free patients with no
inflammation, and were lower than those found in the
cancer patients (Figure 6).
5-azacytidine (AZA) mimics the effect of stem cell 
transplantation -- rehabilitation of the epigenetic markers 
but not the genetic ones
Blood cell samples of the PRE and the ADI groups grown
in the presence of AZA, showed a low frequency of SD
cells for TP53, AML1 and  CEN17, similar to those
observed in the cell samples of the CON and the POST
groups (Figure 2; Columns 1-3 in Table 3). Yet, the
increased frequencies of aneuploidy shown in the PRE
and ADI samples did not return to normal in the pres-
ence of AZA (Figure 3; columns 5 and 6 in Table 3). In
this respect, AZA is mirroring the long term effect of G-
CSF, as shown in peripheral blood lymphocytes of healthy
stem cell donors following in-vivo application of the stim-
ulating factor -- Rehabilitation of the replication pattern
and fixation of the elevated aneuploidy levels [21].
It should be noted that there were no changes in the
high SD values for SNRPN of samples grown in the pres-
ence and the absence of AZA as shown in the cell samples
of the CON group (mean values of 38.6 ± 5.7 and 37.9 ±
7.0, respectively) as well as in those of the ADI group
(mean values of 37.7 ± 3.6 and 38.1 ± 5.0, respectively)
(Figure 2A and 2B; Table 3). Thus, it appears that AZA
abolishes only asynchronous replication that arises from
the malignant condition but not that normally hatched in
the genome.
Discussion
We investigated the temporal order of allelic replication
of two cancer-related genes (TP53 and AML1) and a non-
coding repetitive DNA sequence (CEN17):  TP53  is a
tumor-suppressor gene, the most commonly mutated
gene in human neoplasms (reviewed in [22]); AML1 is an
ETS family gene, involved in the 8;21 -- leukemia-abun-
dant translocations (reviewed in [23]); and CEN17 is an
array associated with the centromere of chromosome 17,
Figure 6 Distribution of lymphocyte samples of patients with 
prostate cancer and cancer-free individuals, with and without in-
flammation of the prostate gland, according to their AML1 and 
CEN17 SD values. The red marked characters indicate the mean val-
ues of the corresponding subgroup; Note, that the SD values of sam-
ples derived from the cancer-free patients with chronic inflammation 
were similar to those of the cancer-free patients with no inflammation, 
and were lower than those found in the cancer patients.
Figure 5 Distribution of bone marrow samples according to their 
AML1 and TP53 SD values.Nagler et al. BMC Cancer 2010, 10:230
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which, as such, is engaged in chromosome segregation
[18]. Normally, these loci exhibit a synchronous mode of
allelic replication. Yet in peripheral blood cells of blood
cancer patients prior to transplantation, each displayed
loss of synchrony and replicated asynchronously, a behav-
ior normally observed in imprinted genes (reviewed in
the introduction). This aberrant replication seen in these
patients appears to be non-disease and non-disease-sta-
tus-specific as we showed that it characterizes various
hematological malignancies and it was displayed both at
diagnosis as well as at advanced stages of the disease. It
was observed at remission and at the relapse of the basic
malignancy. These results are in line with previous stud-
ies reporting that blood cells of patients with hematologi-
cal malignancies taken at diagnosis exhibit a loss of
synchrony of normally biallelically expressed genes
[16,21].
Furthermore, we could use the cancer related replica-
tion marker in bone marrow cell samples to differentiate
between patients prior to transplantation and control
subjects, thereby showing that in hematological malig-
nancies the epigenetic insult is not specific to blood cells,
and it is displayed in bone marrow cells of patients under-
g o i n g  t r e a t m e n t ,  s h o w n  h e r e ,  a s  w e l l  a s  a t  d i a g n o s i s ,
shown previously [15].
However, this abnormal pattern of replication (an epi-
genetic aberration), which is shown to be independent of
disease status, is abolished in lymphocytes derived from
patients following allogeneic stem-cell transplantation.
Yet, the increased aneuploidy level (a genetic aberration)
that accompanies hematological malignancies (shown in
blood cells of patients at diagnosis as well as prior to
transplantation), unlike the epigenetic aberration, is not
reduced to normal following transplantation.
Interestingly, the effect of alloSCT, in respect to replica-
tion adjustment and aneuploidy maladjustment, resem-
bles the long term outcome of granulocyte colony
stimulating factor (G-CSF) treatment displayed in lym-
phocytes of healthy stem-cell donors [21]. Briefly, the
aberrant replication in cells of the donors gradually, in the
course of several weeks after G-CSF administration, read-
justs to normal, while the increased level of sporadic ane-
uploidy remains unchanged. The finding that blood
lymphocytes of hematological patients following alloSCT
exhibit replication and aneuploidic properties similar to
those of the G-CSF treated healthy donors [21] is not sur-
prising. The blood cells of patients following alloSCT are
actually donor cells that were exposed to G-CSF adminis-
tered prior to collection to boost stem cell release.
Whatever the reason, we show here that the aberrant
replication patterns characterizing blood cells derived
from patients with hematological malignancies is com-
pletely eradicated following a successful therapeutic
modality, i.e., alloSCT. As such, this test may find use as a
convenient indicator of full biological recovery and cure.
Hence, the level of asynchrony of a biallelically expressed
locus compared to that of an imprinted (monoallelic)
locus offers a potential epigenetic marker for assessing
the outcome of transplantation. It would allow simpler
determinations of the success of alloSCT in biologically
eradicating the baseline malignancy and yielding a com-
plete cure, a determination now requiring laborious,
costly techniques [24].
Yet, the increased aneuploidy level (a genetic aberra-
tion), unlike an epigenetic aberration, is not reversible.
This is probably corollary to the critical difference, even
on the cellular level, between an epigenetic aberration
and a genetic one; the former is potentially reversible and
the latter is not. This difference enables medicine to take
advantage of cancer-induced epigenetic alterations for
disease control and treatment follow up. As such the irre-
versible nature of aneuploidy explains why the aneuploidy
levels are not reduced (during the course of time) in
blood cells of the donors as well as in those derived from
the recipients. However, it is encouraging that in both
cases they are not elevated and remain the same (steady
Table 3: Levels of significance (P) of the differences between corresponding values in samples grown with and without 
AZA.
TP53 CEN17 AML1 SNRPN Chromosome 17 Chromosome 21
CON
(n = 20)
P > 0.20 P > 0.10 P > 0.05 P > 0.70 P > 0.60 P > 0.50
ADI
(n = 20)
P < 10-13 P < 10-12 P < 10-15 P > 0.50 P > 0.30 P > 0.20
PRE
(n = 14)
P < 10-11 P < 10-9 P < 10-6 ----- P > 0.10 P > 0.40
CON - samples of cancer free subjects; ADI - samples of patients with hematological malignancies obtained at diagnosis; PRE - samples of 
patients with hematological malignancies taken prior to alloSCT; AZA - 5-azacytidine; n - Number of cases tested within each group for each 
locus/chromosome; SD values - columns 1-4; and aneuploidy levels - columns 4 and 5.Nagler et al. BMC Cancer 2010, 10:230
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state). This is because, from a cytogenetic point of view, a
"steady state" of aneuploidy (even at elevated levels) in
contrast to continuous increase in aneuploidy levels
(chromosomal instability) is considered harmless [25].
This is in line with the view that G-CSF applied to healthy
donors is safe [26,27].
Finally, we show here that a demethylating anti-cancer
drug (5-azacytidine), applied in vitro mimics the recuper-
ating effect of transplantation, eradiating the epigenetic
aberration, while leaving the genetic aberration as is.
First, our results indicate a clinical potential for the use of
the replication marker, particularly for drug monitoring.
Second, they further ease the theoretical concerns that
healthy donors are at risk by their being given G-CSF, but
agree with data indicating that healthy donors following
G-CSF administration display alterations in their gene
expression patterns [[28]; see also the next paragraph].
Third, they link the aberrant replication with enhanced
methylation capacity. The latter was expected, as numer-
ous studies have indicated that the epigenetic disequilib-
rium accompanying the cancerous phenotype is
associated with global and specific methylation modifica-
tions [29-31]. Methylation modifications were also
described in blood and cytologically normal cells adja-
cent to solid tumors [32-35].
Yet, allelic counterparts that normally replicate asyn-
chronously are usually differentially methylated
[reviewed in [3]]. Therefore it is reasonable to assume
that the malignancy disrupts the epigenetic symmetry of
alleles achieved during diploidization. This correlates
with the epigenetic gene silencing known to accompany
the cancerous status [29]. Furthermore, there is evidence
that epigenetic gene silencing in cancer is not a localized
event affecting discrete genes, but a generalized condi-
tion that spans broad chromosomal regions [36]. This is
in accord with our results showing that both the tumor-
suppressor  TP53  gene -- a normally biallelically
expressed gene located at band p13.1 of chromosome 17 -
- and the non-coding pericentromeric region of chromo-
some 17 (CEN17) display epigenetic alterations in the
patients' cells.
Interestingly, the demethylating anti-cancer drug AZA
eradicated the aberrant asynchronous replication in the
cells we studied, but had no effect on the asynchronous
replication characterizing a normal imprinted gene. This
is in accord with studies showing that the AZA drug and
its deoxy-derivative (5-aza-2'-deoxycytidine) have pro-
found effects on abnormal cells and more moderate inter-
actions with normal ones. Both these drugs reactivate the
expression of genes that have undergone epigenetic
silencing, particularly when this silencing occurred in a
pathological situation (reviewed in [37]). The two nucleo-
side analogues (5-azacytidine and 5-aza-2'-deoxycyti-
dine) are converted to the deoxy-nucleotide
triphosphates, which may replace cytosine during DNA
replication. As such, they are active only in S-phase [38].
It would be interesting to determine whether other dem-
ethylating anti-cancer drugs also abolish aberrant asyn-
chronous replication exhibited by biallelically expressed
genes associate with pathological situations while disre-
garding asynchronous replications hatched normally in
monoallelically expressed genes. In this context, it is wor-
thy to note that the wide spread of epigenetic aberrations
in neoplasmic cells [29-31], coupled with the reversible
nature of the epigenetic changes, opens a new therapeutic
avenue for the development of new anti-cancer drugs
capable of reversing such aberrant epigenetic traits
(reviewed in [31]). However, any promising anti-cancer
drug, based on this epigenetic therapeutic approach,
must be able to differentiate between the cancer-induced
and normal (inherent) allelic asynchronous replication.
Conclusions
Patients with hematological malignancies display non-
disease-specific epigenetic and genetic aberrations in
their blood cells. These aberrations, detected by simple
molecular-cytogenetic means are displayed in the
patients' cells from the time of diagnosis through to just
before they undergo allogeneic stem cell transplantation
(alloSCT). Thereafter, concomitantly with full remission,
the aberrant epigenetic markers are completely eradi-
cated, leaving the genetic markers unchanged. In fact,
blood cells derived from patients following successful
alloSCT mirror the long-term effects displayed by blood
cells of healthy stem cell donors following administration
of granulocyte colony stimulating factor (G-CSF). Hence,
the donor's cells in the recipient's "environment" behave
as they do in their own "environment." An archetypical
demethylating drug, 5-azacytidine (AZA), which has
recently been approved for the therapy of myeloid malig-
nancies, mimics the effect of alloSCT; AZA applied in
vitro to blood cells of patients prior to alloSCT eradicates
the epigenetic aberrations, leaving unchanged the genetic
ones. Our results, on one hand, ease the theoretical con-
cern about the safety of G-CSF administration to healthy
stem-cell donors and on the other hand, offer a potential
new approach for evaluating the success of transplant or
other treatments for blood cancers, and for long-term fol-
low up of the patients who have overcome a hematologi-
cal malignancy.
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